Portuguese chemistry SME synthesizing stabilizing compounds for biologics and membrane proteins, supporting pharmaceutical drug design consortia.
EXTREMOCHEM is a small Portuguese chemistry company that works at the intersection of chemical synthesis and protein science, developing stabilizing compounds for biological molecules. Their founding project focused on producing novel chemically synthesised compounds to stabilize biologics — a critical challenge in pharmaceutical manufacturing and storage. They subsequently moved into membrane protein research, contributing chemistry and stabilization expertise to a larger academic consortium developing integrated technologies for drug design. In practical terms, they supply the chemical know-how that makes hard-to-handle proteins — especially membrane proteins — workable for structural studies and pharmaceutical applications.
The ExtremoChem project (2016-2017) was built entirely around chemically synthesised compounds for biologic stabilization, and EXTREMOCHEM coordinated it, indicating this is their founding commercial proposition.
ProMeTeus (2019-2023) lists high-throughput membrane protein production and stabilization as a core keyword, extending their stabilization chemistry into this structurally challenging protein class.
ProMeTeus explicitly targets structural studies and drug design, positioning EXTREMOCHEM as a chemistry contributor to early-stage pharmaceutical pipelines.
In their first H2020 engagement (2016-2017), EXTREMOCHEM focused on the chemistry side of biologics stabilization — developing compounds rather than studying protein biology — which reflects a product-oriented, SME-commercialization angle. By 2019 they had joined an academic-led MSCA-RISE consortium squarely focused on membrane proteins, high-throughput production workflows, and drug design, signaling a shift toward research-facing applications of their stabilization expertise. The trajectory is from applied chemistry product development toward structural biology and pharmaceutical R&D support.
EXTREMOCHEM appears to be repositioning from standalone chemistry product development toward serving as a specialist chemistry partner in pharmaceutical and structural biology research consortia — a path that leads toward the membrane protein therapeutics space.
EXTREMOCHEM led a small SME Phase 1 feasibility project as coordinator, which is a solo or near-solo instrument — suggesting they can identify and articulate an innovation opportunity well enough to win competitive EU funding. They later joined ProMeTeus as a participant, which as an MSCA-RISE project involves structured researcher exchanges between academia and industry. With 10 unique consortium partners across 5 countries, their network is modest but genuinely international, consistent with a specialist SME that joins larger consortia for its specific chemistry contribution rather than acting as a network hub.
EXTREMOCHEM has collaborated with 10 unique partners across 5 countries, a footprint consistent with participation in one larger MSCA-RISE consortium plus a small self-led project. Their network skews toward academic and research institutions given the nature of the ProMeTeus project.
EXTREMOCHEM occupies a narrow but commercially valuable niche: the chemistry of making proteins — particularly membrane proteins — stable and usable outside their native environment. This is a genuine bottleneck in biopharmaceutical development and structural biology, and few SMEs offer bespoke chemical stabilizer synthesis combined with hands-on experience in EU-funded drug design consortia. For a consortium building around membrane protein therapeutics or biologics formulation, they bring something most academic partners cannot: a commercial chemistry operation with skin in the product-development game.
